Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
AI drug discovery artificial intelligence Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
BOSTON, MA, June 18, 2026 Curiumâ„¢ has secured a significant legal and commercial milestone after prevailing in a patent...
